The outcome of @entity1 with metastatic @entity2 is poor, with a 1-year survival rate of approximately 35%. We are evaluating the combination of @entity2600 ( @entity2600 , Camptosar) and @entity3003 ( @entity3003 ) in @entity1 with stage IIIB and @entity1149 . Eligible @entity1 include those with histologic or cytologic diagnosis of @entity1149 ; no previous chemotherapy for metastatic @entity2 ; and Eastern Cooperative Oncology Group performance status 0 or 1. The first five @entity1 received @entity2600 at 250 mg/m2 over 90 minutes followed by @entity3003 at an area under the concentration-time curve (AUC) of 5 over 1 hour. Subsequently, the dose of @entity2600 was reduced to 200 mg/m2 in view of @entity1398 in one of five @entity1 . Chemotherapy cycles are repeated every 21 days. @entity1 are reevaluated every two cycles. Of a planned 37 @entity1 , 14 have been enrolled and 9 are evaluable for @entity137 and response at the time of this report. Thirty-two cycles have been administered, with seven 1-week delays and two dose reductions. To date there have been two partial responses and five @entity1 with stable disease; two @entity1 developed progressive disease on therapy. One @entity1 had @entity221 ; other @entity137 included mild @entity788 (n = 1) and @entity4436 (n = 1). The regimen of @entity2600 and @entity3003 administered once every 3 weeks demonstrates early evidence of activity, and is tolerable and convenient. The main @entity137 is hematologic. This study is ongoing and actively accruing @entity1 .

@entity2600 and XXXX in metastatic or recurrent @entity1149 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan', 'CPT-11'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin', 'Paraplatin'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small-cell lung cancer', 'IV non-small-cell lung cancer'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['febrile neutropenia'] @entity4436 :: ('MESH:D004238', 'Disease') :: ['diverticulitis'] @entity221 :: ('MESH:D005334', 'Disease') :: ['neutropenic fever']
@entity3003 :: (MESH:D016190,Chemical) :: ['carboplatin']
